Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4858060

CCC(C)(C)C1CCC(NN)C1.O=C(O)C(F)(F)F

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.36
SLC1A2 P43004 2/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
EPHX1 P07099 1/20 0.30
GRM2 Q14416 1/20 0.30
GRM3 Q14832 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP7 Q9UHL4 1/20 0.30
HRH4 Q9H3N8 1/20 0.30
HRH3 Q9Y5N1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4855744 0.77 DPP8 (0.39) SLC1A2ALDH1A1LMNAMAPTDPP4
SCHEMBL4858067 0.76 GAA (0.32) GAA
Trifluoroacetic Acid SCHEMBL22505630 0.75 PKM (0.38) DPP4DPP8DPP7
Trifluoroacetic Acid SCHEMBL16050159 0.68 PDK1 (0.39) GAANPC1RAB9AEPHX1ALDH1A1
Trifluoroacetic Acid SCHEMBL4114059 0.68 PDK1 (0.39) GAANPC1RAB9AEPHX1ALDH1A1
SCHEMBL18628984 0.67 GRM2 (0.37) GRM2GRM3ALDH1A1LMNAMAPT
Trifluoroacetic Acid SCHEMBL3862637 0.67 PDK1 (0.42) GAANPC1RAB9AEPHX1ALDH1A1
SCHEMBL24429552 0.66 GAA (0.47) GAANPC1RAB9AEPHX1ALDH1A1
Trifluoroacetic Acid SCHEMBL18660259 0.64 TRPV1 (0.33) DPP4DPP8
Trifluoroacetic Acid SCHEMBL697144 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234020-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. 2005-10-20 US claimed
EP-1556059-A1 THROMBOPOIETIN MIMETICS Smithkline Beecham (US) 2005-07-27 EP claimed
WO-2003103686-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-18 WO claimed
US-7414040-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2008-08-19 US disclosed
US-20050234020-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. 2005-10-20 US disclosed
EP-1556059-A1 THROMBOPOIETIN MIMETICS Smithkline Beecham (US) 2005-07-27 EP disclosed
WO-2003103686-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234020-A1 Thrombopoietin mimetics MPL, THPO, TEK GAA 2853/4885SLC1A2 4516/4885NPC1 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.